Fig. 1From: The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocolBayesian adaptive trial design with interim analyses and decision boundaries for single-agent and combination-therapy arms. Green arrows denote efficacy, orange arrows denote futilityBack to article page